Johnson & Johnson's COVID-19 Shot Approved In UK

by Vandana Singh, Benzinga Editor

May 28, 2021 8:31 AM | 27 seconds read | Make a Comment

The single-shot coronavirus vaccine from Johnson & Johnson JNJ has been approved for use in the U.K., making it the fourth vaccine to be used in the country to protect against COVID-19.
The vaccine was 85% effective in stopping severe illness from COVID-19 in the clinical trials.
20 million doses have been ordered for the U.K. that will arrive later in 2021.
Price Action: JNJ shares are up 0.8% at $170.2 during the premarket session on the last check Friday.

Posted In: Biotech News Health Care FDA General Briefs COVID-19 Vaccine United Kingdom

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.